Project Grant R41EB038861
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $314K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Louisville, KY 40204, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $802,973 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop rapid point-of-care molecular imaging of immune activation in acute coronary syndrome and acute myocarditis using targeted microbubble contrast agents. The project applies myocardial contrast echocardiography with phosphatidylserine-incorporating lipid microbubbles (MB-PS) to detect inflammatory activation from...
- The National Heart, Lung, and Blood Institute awarded Actiox LLC $699,468 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) for development of a wearable microneedle-based biosensor for continuous cardiac troponin I monitoring. The assistance type is a Project Grant. Actiox will develop and optimize an electrochemical aptamer-based sensor integrated with microneedle arrays capable of real-time, ultra-sensitive monitoring of cardiac troponin I in interstitial...
- The National Heart, Lung, and Blood Institute awarded Prenosis, Inc. $1,218,102 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate the Heart Failure CardioScore, an artificial intelligence diagnostic tool for acute heart failure in emergency department patients. Prenosis will combine novel biomarkers and clinical data with machine learning to improve diagnostic and prognostic accuracy for acute heart failure, addressing the challenge...
- The National Heart, Lung, and Blood Institute awarded Yale University $445,000 under CFDA 93.837 (Cardiovascular Diseases Research) on August 1, 2026, to develop deuterium metabolic imaging (DMI) as a non-invasive diagnostic tool for hibernating myocardium in coronary artery disease patients. The award is classified as a Project Grant under NIH assistance type R21HL184055. The research addresses a clinical gap: roughly 4 million Americans with heart failure stemming from coronary artery...
- The National Heart, Lung, and Blood Institute awarded Tele-Stethoscope Inc. $406,367 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop Phase I algorithms and demonstrate technical feasibility for a mobile phone–based diagnostic tool that uses acoustic data to predict clinically significant spirometry and echocardiogram findings. The recipient will develop algorithms for predicting FEV1 percent predicted findings using mobile phone–captured...
- The National Heart, Lung, and Blood Institute awarded Stasys Medical Corp $325,648 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to establish ISO 13485–compliant manufacturing for test cartridges supporting the ATLAS platelet function diagnostic platform. The project delivers a scalable production line for single-use test cards containing microfluidic chips with shear-activating force sensors designed to detect platelet micro-clots. Work includes...
- The National Heart, Lung, and Blood Institute awarded 3D Bioanalytix, Inc. $421,400 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance and validate a structural proteomics platform for early detection of protein misfolding–driven cardiovascular diseases. 3D Bioanalytix will optimize and validate the analytical performance and reproducibility of the Amyfold assay, a mass spectrometry–based blood test designed to detect misfolded transthyretin in...
- The National Institute of Biomedical Imaging and Bioengineering awarded the University of Southern California $291,496 on July 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop high-resolution three-dimensional electrical impedance mapping technology for identifying metabolically active atherosclerotic plaques. The project develops a balloon-deployable catheter platform integrating ultrathin, highly...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $902,000 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an abbreviated cardiovascular magnetic resonance imaging solution for time-efficient, cost-effective etiology diagnosis of acute ischemic stroke. The project develops a 10-minute abbreviated cardiovascular MRI protocol designed to identify the underlying cause of acute ischemic...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $186,840 under CFDA 93.837 Cardiovascular Diseases Research on July 3, 2026, for advanced analysis of high-resolution cardiac diffusion tensor imaging (DTI). The funded work develops and applies DTI phenomapping, a voxel-level quantitative analysis approach for cardiac magnetic resonance imaging that resolves distinct microstructural patterns in...